FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
P/E ratio for FibroGen, Inc. (FGEN)
P/E ratio as of 2023: -0.30
According to FibroGen, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.30. At the end of 2022 the company had a P/E ratio of -5.08.
P/E ratio history for FibroGen, Inc. from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.30 |
| 2022 | -5.08 |
| 2021 | -4.47 |
| 2020 | -17.61 |
| 2019 | -48.27 |
| 2018 | -45.02 |
| 2017 | -27.41 |
| 2016 | -21.77 |
| 2015 | -21.43 |
| 2014 | -8.63 |
| 2013 | -69.60 |
| 2012 | -31.93 |